Medical Advocates

Darunavir (Prezista/TMC-114)
  Main Page

New and Noteworthy

Protease Inhibitors: General Data
Journal Data
Conference Data
Pediatric Data
Perinatal  Data

ARV Drugs Main Page Drugs Main Page          Main New/Newsworthy  Home Page      

This web page is best viewed by using INTERNET EXPLORER
Last Update:  March 30, 2018

Documents identified with this icon are in Portable Document Format (PDF) and require the Adobe Acrobat Reader

New and Noteworthy

March 2018

Pediatric Data

Journal  Abstracts, Papers and Commentaries
Pharmacokinetics, Short Term Safety and Efficacy of the Approved Once-Daily Darunavir/r Dosing Regimen in HIV-Infected Children.
Bastiaans DET, Geelen SPM, Visser EG, et al
Pediatr Infect Dis J
. 2018 Feb 22

Characteristics and early outcomes of children and adolescents treated with darunavir/ritonavir-, raltegravir- or etravirine-containing antiretroviral therapy in the Western Cape Province of South Africa.
Nuttall J, Pillay V.

S Afr Med J
. 2018 Feb 1;

Pharmacokinetics of Once-Daily Darunavir/Ritonavir With and Without Etravirine in Human Immunodeficiency Virus-Infected Children, Adolescents, and Young Adults.
Larson KB, Cressey TR, Yogev R,  et al

Pediatric Infect Dis Soc
. 2016 Jun;5(2):131

Safety of darunavir and atazanavir in HIV-infected children in Europe and Thailand.
European Pregnancy and Paediatric HIV Cohort Collaboration (EPPICC) study group in EuroCoord.
Antivir Ther
. 2015 Nov 12.

Darunavir: A Review in Pediatric HIV-1 Infection.
Keating GM.
Paediatr Drugs. 2015 Sep 1.

Model-Based Once-Daily Darunavir/Ritonavir Dosing Recommendations in Pediatric HIV-1-Infected Patients Aged 3 to 12 Years
Brochot A, Kakuda TN, Van De Casteele T,
CPT Pharmacometrics Syst Pharmacol. 2015 Jul;4(7):406-414.

Desensitization to darunavir in a pediatric patient
Cambray-Gutiérrez JC, López-Pérez P, Chávez-García AA,
Rev Alerg Mex
. 2015 Jul-Sep;62(3):251-254

Safety and Efficacy of Darunavir/Ritonavir in Treatment-experienced Pediatric Patients: Week 48 Results of the ARIEL Trial.
Violari A, Bologna R, Kumarasamy N, et al
Pediatr Infect Dis J. 2015 Feb 21.

Pharmacokinetics and efficacy of darunavir/ritonavir once daily in virologically suppressed, treatment-experienced HIV-infected children.
Chokephaibulkit K, Rungmaitree S, Phongsamart W,  et al
HIV Med. 2014 Sep;15(8):511-2.

Early Outcomes of Darunavir- and/or Raltegravir-based Antiretroviral Therapy in Children with Multidrug-Resistant HIV at a Pediatric Center in Botswana.
Kirk BL, Gomila A, Matshaba M,   et al

J Int Assoc Physicians AIDS Care (Chic)
. 2013 Jan 11

Profile of darunavir in the treatment of HIV-infected pediatric and adolescent patients.
Dobroszycki J, Abadi J, Wiznia AA, Rosenberg MG.
Adolesc Health Med Ther
. 2011 Sep 14;2:85-93

The prevalence of darunavir-associated mutations in HIV-1-infected children in the UK.
Donegan KL, Walker AS, Dunn D,
Antivir Ther. 2011 Dec 15.

Pharmacokinetics, safety and efficacy of darunavir/ritonavir in treatment-experienced
children and adolescents
Blanche S, Bologna R, Cahn P, et al 
AIDS. 2009 Aug 30

Managing treatment-experienced pediatric and adolescent HIV patients: role of darunavir.
Neely M, Kovacs A.
Ther Clin Risk Manag. 2009 Jun;5(3):595-615.

Managing treatment-experienced pediatric and adolescent HIV patients: role of darunavir.
Neely M, Kovacs A.
Ther Clin Risk Manag. 2009 Jun;5(3):595-615

Successful rescue therapy with a darunavir/ritonavir and etravirine antiretroviral regimen in a child
with vertically acquired multidrug-resistant HIV-1.
Viganò A, Meroni L, Marchetti G, et al

Antivir Ther. 2008;13(6):839-43.


Perinatal Data

          Journal  Abstracts, Papers and Commentaries
  Pharmacokinetics of Once versus Twice Daily Darunavir In Pregnant HIV-Infected Women.
Stek A, Best BM, Wang J,  et al
J Acquir Immune Defic Syndr. 2015 May 6

Pharmacokinetics of total and unbound darunavir in HIV-1-infected pregnant women.
Colbers A, Moltó J, Ivanovic J, et al 

J Antimicrob Chemother
. 2014 Oct 17

Total and unbound darunavir pharmacokinetics in pregnant women infected with HIV-1: results of a study of darunavir/ritonavir 600/100 mg administered twice daily.
Zorrilla C, Wright R, Osiyemi O, et al
HIV Med. 2013 Jun 3.

Total and unbound darunavir (DRV) pharmacokinetics (PK) in HIV-1-infected pregnant women.
Zorrilla C, Wright R, Osiyemi O,  et al

J Int AIDS Soc
. 2012 Nov 11;15(6):18340

Use of darunavir and enfuvirtide in a pregnant woman.
Sued O, Lattner J, Gun A, et al
. 2008 Dec;19(12):866-7.

ARV Drugs Main Page Drugs Main Page               Main New/Newsworthy  Home Page      

Darunavir (Prezista/TMC114)